CureVac (CVAC) Competitors $2.49 -0.01 (-0.40%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CVAC vs. IDYA, NAMS, KROS, WVE, AKRO, LGND, AMPH, MIRM, SUPN, and CNTAShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include IDEAYA Biosciences (IDYA), NewAmsterdam Pharma (NAMS), Keros Therapeutics (KROS), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Ligand Pharmaceuticals (LGND), Amphastar Pharmaceuticals (AMPH), Mirum Pharmaceuticals (MIRM), Supernus Pharmaceuticals (SUPN), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry. CureVac vs. IDEAYA Biosciences NewAmsterdam Pharma Keros Therapeutics Wave Life Sciences Akero Therapeutics Ligand Pharmaceuticals Amphastar Pharmaceuticals Mirum Pharmaceuticals Supernus Pharmaceuticals Centessa Pharmaceuticals IDEAYA Biosciences (NASDAQ:IDYA) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings. Does the media refer more to IDYA or CVAC? In the previous week, IDEAYA Biosciences had 5 more articles in the media than CureVac. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 3 mentions for CureVac. CureVac's average media sentiment score of 0.97 beat IDEAYA Biosciences' score of 0.10 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral CureVac 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in IDYA or CVAC? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 3.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is IDYA or CVAC more profitable? CureVac has a net margin of 20.72% compared to IDEAYA Biosciences' net margin of 0.00%. CureVac's return on equity of 21.98% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -19.42% -18.63% CureVac 20.72%21.98%15.72% Which has more risk & volatility, IDYA or CVAC? IDEAYA Biosciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Which has preferable earnings & valuation, IDYA or CVAC? IDEAYA Biosciences has higher earnings, but lower revenue than CureVac. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$23.39M94.37-$112.96M-$2.33-10.96CureVac$58.18M9.58-$281.58M$0.554.53 Does the MarketBeat Community believe in IDYA or CVAC? IDEAYA Biosciences received 112 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 70.98% of users gave IDEAYA Biosciences an outperform vote while only 54.35% of users gave CureVac an outperform vote. CompanyUnderperformOutperformIDEAYA BiosciencesOutperform Votes13770.98% Underperform Votes5629.02% CureVacOutperform Votes2554.35% Underperform Votes2145.65% Do analysts prefer IDYA or CVAC? IDEAYA Biosciences currently has a consensus target price of $53.67, suggesting a potential upside of 110.13%. CureVac has a consensus target price of $10.00, suggesting a potential upside of 301.61%. Given CureVac's higher possible upside, analysts plainly believe CureVac is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94CureVac 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryIDEAYA Biosciences beats CureVac on 10 of the 19 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$559.70M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio4.534.4283.5712.93Price / Sales9.58375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book0.7010.126.936.25Net Income-$281.58M$153.61M$119.12M$225.93M7 Day Performance-6.74%-2.00%-1.83%-1.32%1 Month Performance-10.11%-7.47%-3.64%0.60%1 Year Performance-54.64%31.80%31.64%26.23% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.5275 of 5 stars$2.49-0.4%$10.00+301.6%-55.3%$559.70M$58.18M4.531,172IDYAIDEAYA Biosciences4.1381 of 5 stars$25.54-1.2%$53.67+110.1%-17.1%$2.24B$23.39M0.0080Analyst ForecastNAMSNewAmsterdam Pharma2.936 of 5 stars$20.01-15.5%$33.80+68.9%+110.6%$2.19B$14.09M0.0057Insider TradeNews CoverageGap DownHigh Trading VolumeKROSKeros Therapeutics3.4913 of 5 stars$54.14+1.0%$88.89+64.2%+80.5%$2.17B$150,000.000.00100WVEWave Life Sciences4.857 of 5 stars$14.26+0.4%$21.89+53.5%+174.2%$2.17B$113.31M-12.85240Analyst RevisionAKROAkero Therapeutics4.0502 of 5 stars$30.64-1.3%$46.83+52.9%+83.8%$2.17BN/A0.0030Analyst ForecastInsider TradeLGNDLigand Pharmaceuticals4.9545 of 5 stars$111.56-0.2%$144.83+29.8%+91.9%$2.11B$131.31M44.4580AMPHAmphastar Pharmaceuticals4.7262 of 5 stars$44.09+1.1%$63.00+42.9%-22.1%$2.10B$644.40M14.701,761MIRMMirum Pharmaceuticals4.2959 of 5 stars$43.69+3.8%$57.73+32.1%+36.1%$2.02B$186.37M0.00140Analyst RevisionSUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive NewsCNTACentessa Pharmaceuticals4.0515 of 5 stars$16.74-0.5%$25.83+54.3%+144.7%$1.91B$6.85M0.0072 Related Companies and Tools Related Companies IDYA Competitors NAMS Competitors KROS Competitors WVE Competitors AKRO Competitors LGND Competitors AMPH Competitors MIRM Competitors SUPN Competitors CNTA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVAC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
